Member Info for Laura2022

Im assuming PYC will be involved due to our joint venture

Inaphaea has signed a Master Services Agreement and Project Statement of Work with a UK based biotech company.  The first invoice has been issued relating to the work, with subsequent invoices anticipated at milestones during the project period.

This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023.  The project is investigating possible anti-cancer properties of a range of novel molecules using a phenotypic assay and will benefit from the use of patient-derived cells ("PDCs") from Inaphaea's biobank, recently acquired from the liquidated assets of Imagen. The Directors believe that ready access to in-house PDCs will simplify access to suitable in vitro cancer disease models.

What is a public offering please ?

Bicycle are a important client of PYC so surely this means they will be looking for us to develop these drug pipeline?

It does look like that Kidlington

I assume to allow CGT allowance to be applied going forward

Some very big buys here today , good to see

On HL they wouldn't give a quote to buy towards closing time

Buys have shown as sells for days now

Please at least read Stephens posts yesterday

Physiomics

is proud to have collaborated with

@CellCentric

to support the clinical development of their lead asset CCS1477 (now inobrodib) using our expertise in mathematical modelling. Great to read about these promising results in early trial.

CellCentric, an innovative UK-based biotechnology company, today announces a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.

As part of the collaboration, Astrid Ruefli-Brasse, Vice President, Tumour Biology, Pfizer Worldwide Research & Development, will join CellCentric’s Scientific Advisory Board and Sriram Krishnaswami, Vice President and Development Head, Multiple Myeloma, Pfizer Global Product Development, will serve as an advisor to CellCentric.

Today’s agreement follows the US Food and Drug Administration’s (FDA) recent granting of a Fast Track designation for inobrodib to treat patients with late-stage relapsed refractory multiple myeloma (RRMM) and orphan drug designation in MM. CellCentric's ongoing blood cancer trial (NCT04068597) involves patients with a range of haematological malignancies including multiple myeloma, but also non-Hodgkin lymphoma, acute myeloid leukaemia, and higher-risk myelodysplastic syndrome (MDS). 

CellCentric plans to announce its expansion cohort data at the 65th ASH Annual Meeting and Exposition which will take place December 9-12, 2023, in San Diego. This will include data from a trial of inobrodib both as a monotherapy and in combination with pomalidomide and plus dexamethasone.

See the post tonight from someone called Kidlington

There was a cancer drug test PYC helped with that got a $25mln deal from Pfizer

9f you look at the historic news PYC get royalties on that I believe

Looks like this buikding on the Sheffield University RNS from before (see below )

The project is expected to be concluded over the next two months, and a longer-term collaboration is currently under discussion.

 

Physiomics CEO, Dr Jim Millen commented:

"We are delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities. We look forward to working with Dr Campbell and her colleagues and believe that both our analytical capabilities, as well as our contacts and experience within the pharmaceutical industry, could add real value to the initiative

Thanks for the update

I really wish people could discuss things politely on these boards, it seems the last 6 months has brought the worst side of people out

Seems to be back in the news alot recently, and PYC dosing tech should surely be of benefit

This is from the PYC website

Personalised Dosing Tool Development

 

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical trial

 

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

 

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients

Thankyou Stephen

It is interesting move away from animal testing of cancer drugs

Looks quite interesting

Ig they can gain the finance, I was lucky tò have a share receive a takeover offer today STM so I have sold and looking for a new investment

I will look at AMTE tonight

I also think PYC which is fully funded and a small market value of £1.5mln and £800,000 in cash is also a potential target

At 70p

Had bought these for the dividend last year

Agree Stoehen

I got the email to HL but only gave me 24hrs to transfer funds so was not possible

As Kidlington says ,we now have £750k and now awaiting the new developments, in the email they said the new areas would offer larger growth opportunities and that PYC are well positioned to win significant portion of the market share ( i have paraphrased) this was on top of the £1.5mln pipeline and they said for the first time I 3 years they have a "pipeline " which is verifiable and would represent double the 2023 revenues if all converted

Hi Kidlington

Apologies ,I have been away,I will put the summary on later tonight

Good luck if you do chose to invest

Porky

Please at least read the previous RNS

They don't need to merge and don't have a high cash burn,in fact they had enough tillid 2024 sp clearly this funds were for expansion

Pipeline: Discussions ongoing with over 25 largely new potential clients regarding projects with an estimated total value of over £1.5m which could be commenced in financial year 2024.

In order to further develop its business and accelerate growth, the Company is raising funds to carry out activities including:

· Further expansion and diversification of its client base;

· Expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and

· Exploration of opportunities around its personalised oncology software offering.

 

Yes Aim999

And Kidlington did some calculations that at £1.4mln market value at 1p and with over £750,000in cash it would be possible for something like YGEN.

I think they offered £16mln for YGEN ?

Hello

Yes, I received a reply and will post s summary today ,I was assured that the funding will be used to exponential grow the company as some joint ventures in the personalised medicine would be helped .

I was assured that this would see immediate benefits in coming weeks

I will post the summary tonight